Methods Analytics is pleased to announce that it will be working in association with Bresmed, a life sciences and health economics company and Alnylam Pharmaceuticals, to deliver a focused, bespoke HES analysis project. The project will look at the rare condition hATTR amyloidosis, across England and will support research work around population incidence, burden and unmet need. This work builds upon Methods Analytics’ growing capability within the LifeSciences space.